10-Q: Amylyx Pharmaceuticals Reports Q3 2024 Results, Focuses on Pipeline After ALS Drug Discontinuation

Amylyx Pharmaceuticals reports a net loss for Q3 2024 and focuses on its pipeline after discontinuing its ALS drug, RELYVRIO/ALBRIOZA.

Summary

• Amylyx Pharmaceuticals reported a net loss of $72.7 million for the third quarter of 2024, compared to a net income of $20.9 million in the same period last year.
• The company's product revenue decreased significantly to $0.4 million, down from $102.7 million in Q3 2023, due to the discontinuation of RELYVRIO/ALBRIOZA for ALS.
• Operating expenses totaled $76.1 million, including a $36.2 million charge for acquired in-process research and development related to the acquisition of avexitide.
• Research and development expenses were $21.2 million, a decrease from $30.0 million in Q3 2023, primarily due to reduced spending on ALS programs.
• Selling, general, and administrative expenses decreased to $17.8 million from $48.7 million in the same quarter last year, reflecting restructuring efforts.
• The company completed the acquisition of avexitide for $36.2 million, which is intended for the treatment of hyperinsulinemic hypoglycemia.
• Amylyx expects to begin a Phase 3 program for avexitide in post-bariatric hypoglycemia in the first quarter of 2025.
• Positive topline results were reported from the Phase 2 HELIOS trial of AMX0035 for Wolfram syndrome, with a Phase 3 program update expected in 2025.
• The Phase 2b/3 ORION trial of AMX0035 for progressive supranuclear palsy is ongoing, with interim data expected in mid-2025.
• A Phase 1 trial of AMX0114 for ALS is planned to begin in Canada by the end of 2024 or early 2025.
• As of September 30, 2024, Amylyx had cash, cash equivalents, and marketable securities of $234.4 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline, the significant financial losses and discontinuation of a key product raise concerns. The company's future success is highly dependent on the success of its pipeline, which is still subject to significant risks.

Positives

• The company successfully acquired avexitide, expanding its pipeline into endocrine conditions.
• Positive topline results from the HELIOS trial of AMX0035 for Wolfram syndrome indicate potential for future development.
• The company is advancing its pipeline with ongoing trials for PSP and planned trials for ALS.
• Amylyx has a substantial cash position of $234.4 million to support its operations and clinical programs.
• The company has significantly reduced operating expenses through restructuring efforts.

Negatives

• The company experienced a significant net loss of $72.7 million in Q3 2024, a sharp contrast to the net income in the same period last year.
• Product revenue decreased dramatically due to the discontinuation of RELYVRIO/ALBRIOZA, eliminating a major revenue stream.
• The company incurred a substantial $36.2 million charge for acquired in-process research and development.
• The company has incurred significant losses from operations and has an accumulated deficit of $569.1 million.
• The company is facing ongoing legal proceedings, including a class action lawsuit and a derivative complaint.

Risks

• The company's future success is heavily dependent on the successful development and commercialization of AMX0035 and avexitide.
• Regulatory approvals for AMX0035, avexitide, and other product candidates are not guaranteed and are subject to delays and uncertainties.
• The company relies on third parties for manufacturing and clinical trials, which introduces risks of delays and performance issues.
• The market for AMX0035 and avexitide may be smaller than expected, and market acceptance is not guaranteed.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company's intellectual property rights may be challenged or circumvented by competitors.
• The company is subject to risks related to economic uncertainty, geopolitical instability, and potential cyber-attacks.
• The company may require substantial additional funding in the future to meet its financial needs and to pursue its business objectives.

Future Outlook

Amylyx plans to focus on its pipeline, including advancing avexitide into Phase 3 trials for PBH, continuing the ORION trial for PSP, and initiating a Phase 1 trial for AMX0114 in ALS. The company believes its existing cash will be sufficient for at least one year.

Management Comments

• The company is actively engaging in discussions with the broader congenital HI community to develop a path forward.
• Amylyx is currently planning to focus on 120-minute AUC as the C-peptide measure for future studies.
• We are engaging with stakeholders, including the FDA, and planning for a single Phase 3 clinical trial and will share additional details on the clinical trial design once finalized.
• We will continue to collect available data on survival and to share learnings from PHOENIX to help inform future ALS research.

Industry Context

The discontinuation of RELYVRIO/ALBRIOZA highlights the challenges in developing treatments for neurodegenerative diseases. The company's shift towards other indications and the acquisition of avexitide reflect a strategic pivot to diversify its pipeline and address unmet needs in other therapeutic areas.

Comparison to Industry Standards

• The significant decrease in revenue following the discontinuation of RELYVRIO/ALBRIOZA is a major setback compared to other pharmaceutical companies with established products.
• The $36.2 million charge for acquired in-process research and development is a common occurrence in the biotech industry when acquiring assets with no alternative future use.
• The reduction in operating expenses through restructuring is a typical response to financial challenges, similar to actions taken by other companies in the sector.
• The positive topline results from the HELIOS trial are encouraging, but the company still needs to demonstrate efficacy in larger Phase 3 trials, which is a common hurdle for biotech companies.
• The company's cash position of $234.4 million is relatively strong compared to other companies at a similar stage of development, but it will need to manage its cash burn carefully.

Legal Proceedings

• A putative class action lawsuit was filed against the Company and certain of its current and former officers alleging materially false and misleading statements related to the commercial results and prospects for RELYVRIO.
• A derivative complaint was filed against certain current and former director and officer defendants, naming the Company as nominal defendant, alleging violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, insider trading, and unjust enrichment.

Stakeholder Impact

• Shareholders are negatively impacted by the significant net loss and the discontinuation of a key product.
• Employees have been impacted by the restructuring plan, which included a 70% reduction in workforce.
• Patients with ALS have been impacted by the discontinuation of RELYVRIO/ALBRIOZA, though a free drug program was offered to those already on treatment.
• Patients with Wolfram syndrome and PSP may benefit from the ongoing development of AMX0035.
• Patients with hyperinsulinemic hypoglycemia may benefit from the development of avexitide.

Next Steps

• The company expects to begin a Phase 3 program for avexitide in PBH in the first quarter of 2025.
• The company expects to provide an update on the Phase 3 program for AMX0035 in Wolfram syndrome in 2025.
• The company expects interim data from the ORION trial of AMX0035 for PSP in mid-2025.
• The company plans to begin a Phase 1 trial of AMX0114 for ALS in Canada by the end of 2024 or early 2025.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMX0035, avexitide, Wolfram syndrome, progressive supranuclear palsy, ALS, hyperinsulinemic hypoglycemia, clinical trials, biotechnology, pharmaceuticals, net loss, product revenue, research and development, restructuring, acquisition